[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,86,114,135,162,196,219,241,264,298,327,353,377,402,423,448],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100635432","sivelestat-sodium-as-an-adjunct-to-endovascular-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100635432",false,"NCT07552610","Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;\n* 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1\u002FM2 segment of the middle cerebral artery) confirmed by CTA\u002FMRA\u002FDSA;\n* 3.Undergoing mechanical thrombectomy;\n* 4.Age between 18-80 years, both male and female;\n* 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;\n* 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the \"last known well\" (LKW);\n* 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;\n* 8.ASPECTS ≥3 for anterior circulation occlusion;\n* 9.Written informed consent provided by the patient or their legal representative.\n\nExclusion Criteria:\n\n* 1．Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;\n* 2．Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;\n* 3．Seizure at stroke onset that precludes assessment of the baseline NIHSS score;\n* 4．Bilateral dilated pupils;\n* 5．Known allergy to sivelestat sodium or any of its excipients;\n* 6．Severe allergy or absolute contraindication to iodinated contrast agents;\n* 7．Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy;\n* 8．Blood glucose \\\u003C50 mg\u002FdL (2.8 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL);\n* 9．Platelet count \\\u003C50 \\* 10⁹\u002FL;\n* 10．Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with INR \\>1.7, or oral anticoagulant treatment within the previous 48 hours;\n* 11．Severe renal failure, defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL), glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin, or requirement for hemodialysis or peritoneal dialysis;\n* 12．Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);\n* 13．Suspected vasculitis or septic embolism;\n* 14．Suspected aortic dissection;\n* 15．Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;\n* 16．Significant mass effect with midline shift;\n* 17．Evidence of internal carotid artery dissection causing flow limitation;\n* 18．Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;\n* 19．Pregnant or breastfeeding women;\n* 20．Confirmed rheumatic or autoimmune disease with long-term use of immunosuppressants or corticosteroids;\n* 21．Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);\n* 22．Participation in another clinical trial that may interfere with the results of this study;\n* 23．Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.","ALL","18 Years","80 Years",{"count":20,"type":21},868,"ESTIMATED","INTERVENTIONAL",[24],"NA","Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.",[27,28,29,30],"Acute Ischemic Stroke","Large Vessel Occlusion","Thrombectomy","Neutrophil Extracellular Trap Formation",[32,33,34],"Endovascular Thrombectomy","Sivelestat Sodium","Neutrophil elastase","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":36,"type":39},{"date":42,"type":21},"2029-05-31",{"name":44,"class":45},"Xuanwu Hospital, Beijing","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100633674","the-recana-for-lower-extremity-venous-obstructions-and-in-stent-restenosis-registry-100633674","NCT07529756","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry (\"The CALIBER Registry\")","CALIBER","INCLUSION CRITERA:\n\nA. Native Vessel:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Proximal lower extremity obstruction\u002Focclusion involving the femoral, common femoral, iliac veins, or inferior vena cava (IVC), alone or in combination that in the opinion of the investigator, treatment with the Recana would benefit the patient\n3. INC-3: Recana Thrombectomy Catheter System must enter vasculature\n4. INC-4: Willing and able to provide written informed consent\n\nB. In-Stent Restenosis:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Subjects with stents implanted greater than 6 weeks prior to index procedure\n3. INC-3: Location of thrombosed stents in proximal lower extremity deep vein segments including common femoral, external iliac, common iliac vein, or inferior vena cava alone or in combination that in the opinion of the investigator treatment with the Recana would benefit the patient\n4. INC-4: Recana Thrombectomy Catheter System must enter vasculature\n5. INC-5: Willing and able to provide written informed consent\n\nEXCLUSION CRITERA\n\nA. Native Vessel:\n\n1. EXC-1: IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n2. EXC-2: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n3. EXC-3: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n4. EXC-4: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n5. EXC-5: Severe, life-threatening allergy to iodine or contrast dye\n6. EXC-6: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n7. EXC-7: Life expectancy less than 1 year\n8. EXC-8: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n9. EXC-9: Known hypercoagulable states that, in the opinion of the investigator, cannot be medically managed throughout the study period\n10. EXC-10: Inability to secure venous access and cross lesion\n11. EXC-11: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n12. EXC-12: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed\n\nB. In-Stent Restenosis:\n\n1. EXC-1: Exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel\n2. EXC-2: Stent failure caused by undersizing or malapposition of the stent(s) \\[For example, the segment of a stent in the iliac vein that is not wall apposed or cannot be apposed to the wall after balloon dilation is excluded. The segment of a stent that extends into the IVC that is not wall apposed would not be excluded.\\]\n3. EXC-3: Stents compressed to \\\u003C6mm that remain \\\u003C6mm after balloon dilation\n4. EXC-4: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n5. EXC-5: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n6. EXC-6: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n7. EXC-7: Severe, life-threatening allergy to iodine or contrast dye\n8. EXC-8: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n9. EXC-9: Life expectancy less than 1 year\n10. EXC-10: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n11. EXC-11: Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n12. EXC-12: Inability to secure venous access and cross lesion\n13. EXC-13: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n14. EXC-14: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed",{"count":56,"type":21},87,"1 Year","OBSERVATIONAL","The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions. The main questions the study aims to answer are:\n\n* What is the observed rate of safety events through the 30-day follow-up?\n* What is the rate of technical success (acute procedural success) achieved at the index procedure?\n\nParticipants already undergoing treatment with the Recana as part of their regular medical care will be followed for 1 year.",[61,62,63,64,65,66,29],"Chronic Venous Disease","Chronic Venous Insufficiency, CVI","Venous Thrombosis","Thrombosis (Stent Thrombosis)","Thrombosis, Venous","Embolism and Thrombosis",[68,69,70,71,72,73,74],"in-stent restenosis","venous obstruction or occlusion","thrombus","emboli","CALIBER Registry","recanalization","debulking","NOT_YET_RECRUITING","2026-05-07",{"date":78,"type":39},"2026-05-12",{"date":80,"type":21},"2026-06",{"date":82,"type":21},"2029-03",{"name":84,"class":85},"Intervene, Inc.","INDUSTRY",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":58,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100620892","michigan-initial-experience-using-tigertriever-for-thrombectomy-100620892","NCT07363525","Michigan Initial Experience Using Tigertriever for Thrombectomy","MIGHTY","Inclusion Criteria:\n\n1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.\n2. Tigertriever was used as the first line treatment in the target vessel.\n3. A signed informed consent.\n4. Age ≥ 18.\n\nExclusion Criteria:\n\n-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and\u002For endovascular therapy in the last 3 months.\n\n3\\. pre-stroke disability (pre-stroke mRS ≥ 2).",{"count":94,"type":21},150,"90 Days","The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.",[98,29,99],"Blood Clot","Ischemic Stroke",[70,101,102,103],"Clot","Device","Stroke","2026-05-06",{"date":106,"type":39},"2026-05-08",{"date":108,"type":39},"2026-01-15",{"date":110,"type":21},"2028-12-31",{"name":112,"class":45},"Henry Ford Health System",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":113},"100527109","endovascular-therapy-versus-best-medical-treatment-for-acute-large-vessel-occlusion-stroke-with-low-nihss-100527109","NCT06143488","Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS","1. Aged 18 years or older;\n2. The time from onset of acute ischemic stroke to arterial puncture is within 24 hours. Onset time is defined as the patient's Last Known Well (LKW);\n3. Low NIHSS score (2-5 points), with at least one of the following items:\n\n   1. Altered mental status (lethargy or worse);\n   2. Facial palsy (facial weakness score ≥ 1 point);\n   3. Motor dysfunction (limb weakness score ≥ 1 point);\n   4. Aphasia (language disturbance score ≥ 1 point);\n   5. Hemispatial neglect (neglect score ≥ 1 point);\n4. Intracranial internal carotid artery, proximal M1 or M2 segment of middle cerebral artery occlusion (excluding tandem lesions) confirmed by cerebral CTA\u002FMRA\u002FDSA before randomization, which is identified as the culprit vessel for stroke;\n5. All patients receive CTP\u002FMR perfusion imaging, with a volume of perfusion delay (Tmax\\>6 s) ≥ 50 mL;\n6. Written informed consent is obtained from the patient or legal surrogate, with agreement for long-term follow-up.",{"count":121,"type":21},264,[24],"Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END).\n\nConsidering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since these patients were typically excluded from the pivotal EVT trials.\n\nThe current study aimed to further test the hypothesis that endovascular therapy would be superior to medical management with respect to functional recovery among low NIHSS patients caused by acute large-vessel occlusion in the anterior circulation.",[27,125,29],"Mild Neurocognitive Disorder","2026-04-27",{"date":128,"type":39},"2026-04-30",{"date":130,"type":39},"2024-02-07",{"date":132,"type":21},"2028-03-31",{"name":134,"class":45},"First Affiliated Hospital of Wannan Medical College",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":113},"100634025","investigation-of-brain-blood-flow-changes-in-acute-ischemic-stroke-patients-after-successful-endovascular-thrombectomy-100634025","NCT07534319","Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy","RESTORE-AIS","Inclusion Criteria:\n\n* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of a family member. Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.\n\nExclusion Criteria:\n\n* Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.\n* Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.\n* Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute\u002Fsubacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).\n* Symptomatic increased intracranial pressure.\n* Presence of intracranial haemorrhage type ≥2 according to the Heidelberg classification.\n* New onset of seizure.",{"count":143,"type":21},100,"Introduction:\n\nEndovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.\n\nStudy population:\n\nAdult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.\n\nObjective(s):\n\nPrimary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.\n\nSecondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.\n\nOutcomes:\n\nClinical outcomes:\n\n* 90-day functional outcome.\n* Functional outcome at hospital discharge.\n* Neurological deterioration during hospitalization.\n* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.\n* Radiologically confirmed infarct lesion progression within the reperfused tissue.\n* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes\n\nStudy design:\n\nSingle-center prospective observational cohort study\n\nMeasurements and procedures:\n\nIncluded patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.\n\nNumber of Participants:\n\nTarget sample size: 100 patients\n\nGiven the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.\n\nStudy period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.\n\nStudy Centre:\n\nClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich\n\nStatistical Considerations:\n\nThe association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.",[146,29,147,148],"Acute Cerebrovascular Accident","Cerebral Revascularization","No Reflow Phenomenon",[27,29,150,147,148,151,152],"Reperfusion Failure","BOLD-CVR","Advanced Haemodynamic Imaging","2026-04-09",{"date":155,"type":39},"2026-04-16",{"date":157,"type":39},"2025-06-01",{"date":159,"type":21},"2027-12-01",{"name":161,"class":45},"University of Zurich",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":113},"100633435","head-cooling-in-ischaemic-stroke-patients-undergoing-endovascular-thrombectomy-coolhead-2b-100633435","NCT07526649","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","COOLHEAD-2B","Inclusion Criteria:\n\n* Acute anterior circulation ischaemic stroke planned for endovascular thrombectomy\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score \\>2\n* Core body temperature \\\u003C35°C at admission\n* Uncontrolled hypertension (≥185\u002F110 mmHg despite treatment in IVT-eligible patients)\n* Known contraindications to hypothermia (e.g., haemodynamic instability, symptomatic bradyarrhythmia, cryoglobulinaemia, sickle cell disease, cold agglutinins)\n* Vasospastic disorders (e.g., Raynaud's phenomenon)\n* Skin lesions preventing secure application of the cooling cap\n* Inability to participate in 90-day follow-up",{"count":171,"type":21},182,[24],"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.",[103,27,175,176,29,177,178,179,28],"Brain Ischemia","Ischaemic Stroke","Endovascular Procedures","Reperfusion Injury","Cooling",[181,182,183,184,185,186],"Head cooling","Selective brain cooling","Endovascular thrombectomy","Therapeutic hypothermia","Penumbra","Neuroprotection",{"date":188,"type":39},"2026-04-13",{"date":190,"type":21},"2026-04-10",{"date":192,"type":21},"2029-06-30",{"name":194,"class":195},"Auckland City Hospital","OTHER_GOV",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":217,"locationsCount":113},"100632656","phase-2-intra-arterial-methylprednisolone-after-endovascular-thrombectomy-100632656","NCT07516522","Intra-arterial Methylprednisolone After Endovascular Thrombectomy","Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18-80 years old;\n* The time from onset to randomization was within 24 hours;\n* Large vessel occlusive stroke in the anterior circulation confirmed by CTA\u002FMRA\u002FDSA (Including intracranial segment of internal carotid artery, M1 or M2 segment of middle cerebral artery) and the vessel responsible for the signs and symptoms of acute ischemic stroke;\n* NIHSS score \\>= 6 points\n* Alberta Stroke Program Early Diagnosis (ASPECTS) score of NCCT \\>=3;\n* Successful endovascular thrombectomy (eTICI 2b50-3)\n* Written informed consent signed by patients or their family members\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by computed tomography (CT) or magnetic resonance imaging (MRI);\n* Prestroke mRS score \\>= 2\n* pregnant or lactating patients\n* Allergy to iodinated contrast media, or methylprednisolone sodium succinate\n* Participating in other clinical research;\n* Inherited\u002Facquired hemorrhagic diathesis (coagulation factor deficiency) or oral anticoagulation with international normalized ratio (INR) \\>1.7\n* History of major bleeding within the past 1 month (gastrointestinal\u002Fgenitourinary hemorrhage)\n* Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m\\^2 or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl));\n* Terminal illness with life expectancy \\\u003C6 months;\n* Blood glucose \\\u003C 2.8mmol\u002FL (50mg\u002Fdl) or \\> 22.2mmol\u002FL (400mg\u002Fdl);\n* Intracranial aneurysm, arteriovenous malformation, or space-occupying brain tumor with mass effect on imaging\n* Active systemic infectious disease\n* Anticipated inability to complete follow-up\n* Intraoperative DSA showed vascular perforation, dissection, and contrast extravasation;\n* Puncture to recanalization was more than 90 minutes;\n* Total thrombectomy passes \\>3",{"count":205,"type":21},210,[207],"PHASE2","The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg\u002Fkg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 178 patients (n=89 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 15% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=210 patients (n=105 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.",[210,29,28],"Ischemia Stroke","2026-03-31",{"date":213,"type":39},"2026-04-08",{"date":211,"type":39},{"date":216,"type":21},"2027-12-31",{"name":218,"class":45},"Tang-Du Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":113},"100413423","immunological-response-assessment-after-acute-ischemic-stroke-treated-with-endovascular-therapy-impress-100413423","NCT04663399","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy","IMPRESS","Inclusion Criteria:\n\n* Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,\n* Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent);\n* Affiliated or beneficiary of a social security scheme or equivalent.\n\nNon inclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Patient benefiting from a legal protection measure\n\nExclusion Criteria:\n\nNone.",{"count":228,"type":21},1200,"IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24\u002F36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.",[99,29],"2026-01-21",{"date":233,"type":39},"2026-01-23",{"date":235,"type":39},"2023-02-23",{"date":237,"type":21},"2028-05-23",{"name":239,"class":240},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":251,"studyType":58,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100615466","endothelial-glycocalyx-and-inflammatory-response-changes-in-patients-with-acute-stroke-undergoing-mechanical-thrombectomy-100615466","NCT07292974","ENDOTHELIAL GLYCOCALYX AND INFLAMMATORY RESPONSE CHANGES IN PATIENTS WITH ACUTE STROKE UNDERGOING MECHANICAL THROMBECTOMY","DYNAMIC CHANGES OF ENDOTHELIAL GLYCOCALYX AND INFLAMMATORY RESPONSE IN PATIENTS WITH ACUTE STROKE TREATED WITH MECHANICAL THROMBECTOMY","DEGIMT","Inclusion Criteria: all patients older than 18 years with a diagnosis of acute IS confirmed by brain CT or MRI, and to whom MT will be performed, regardless of whether they are previously received thrombolysis.\n\nExclusion Criteria: patients under the age of 18, patients with diagnosed with hemorrhagic stroke, patients with acute infection, autoimmune illness, malignant disease, trauma, pregnant women or patients who will refuse to participate in research.",true,{"count":94,"type":21},"2 Days","Ischemic stroke (IS) is one of the leading causes of mortality and disability. Treatment of IS is based on reperfusion methods, thrombolysis and mechanical thrombectomy (MT). However, there are significant limitations in their implementation and success. Also, there is a mismatch between successful recanalization of the blood vessel, recovery of the neurological status as well as treatment outcome. Precisely for these reasons, there is a need for a better understanding of pathophysiology events in the acute IS and for the development of new therapeutic procedures that would include neuroprotection, modification of the inflammatory response and preservation of the integrity of the blood-brain barrier. Acute IS occurs as a result of a blood vessel blockage, which leads to ischemic damage to the brain parenchyma. It causes an early inflammatory response that is extremely complex, involving a large number of inflammatory cytokines whose dynamics and role in the pathophysiology of IS are insufficiently investigated. It is known that inflammatory processes damage the endothelial glycocalyx (EG), a thin luminal layer of the endothelium that has numerous functions such as maintaining the integrity of blood vessels and regulating tone, and itself participates in the inflammatory response. In the brain, EG is a key regulator of the integrity of the blood-brain barrier, and its damage makes the barrier more permeable, which can lead to edema and the passage of potentially harmful substances. Clinical studies have shown that there is a possible relationship between the prognosis of patients with IS and the concentration of EG breakdown products in the peripheral blood. However, the relationship between changes in EG and the inflammatory process in the context of IS, and especially in relation to available treatment methods, remains unclear. The aim of the proposed study is to determine and analyze the dynamics of concentrations of EG degradation products and inflammatory cytokines in patients with acute IS during and after MT. This study would include all adult patients with acute IS who will undergo MT, and the concentrations of EG degradation products and inflammatory cytokines would be determined by the enzyme immunoassay method from peripheral blood and blood samples from the cerebral circulation after reperfusion. The obtained results will be correlated with the collected data on the neurological condition of the patient before and after the intervention, the type and course of the intervention performed, the course and duration of hospital treatment, the occurrence of complications and the outcome of treatment.",[103,29,254],"Endothelial Glycocalyx","2025-12-05",{"date":257,"type":39},"2025-12-18",{"date":259,"type":21},"2026-01",{"date":261,"type":21},"2030-10",{"name":263,"class":45},"Clinical Hospital Centre Zagreb",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":113},"100611048","anesthesia-management-in-endovascular-therapy-for-ischemic-stroke---2-100611048","NCT07235514","Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2","General Anesthesia Versus Procedural Sedation in Endovascular Therapy for Anterior Circulation Large Vessel Occlusion Stroke: A Multicenter Prospective Randomized Trial","AMETIS 2","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute ischemic stroke with an occlusion of the intracranial internal carotid artery and\u002For the proximal middle cerebral artery (M1-M2) with or without association of extracranial occlusion of the cervical internal carotid artery (tandem lesion)\n* Eligible for mechanical thrombectomy according to international guidelines\n* Informed and signed consent of patient, or if he is unable to consent the consent of patient's relative or emergency procedure in the absence of relative\n* National health insurance\n\nExclusion Criteria:\n\n* Coma or altered vigilance defined as a score ≥ 2 on the level of consciousness 1A subscale of the NIHSS\n* Premorbid disability defined as a mRS \\> 2\n* Posterior circulation stroke\n* Associated cerebral hemorrhage\n* Stroke complicating another acute illness or postoperative stroke\n* Emesis at arrival in angiosuite\n* Allergy to anesthetic medication\n* Pregnant or breast-feeding women\n* Adult under the protection of the law",{"count":273,"type":21},958,[24],"The goal of this clinical trial is to learn what is the best anesthetic management in participants with severe stroke that require a medical intervention called mechanical thrombectomy (MT) done to open the occluded brain vessel.\n\nThe main question it aims to answer is:\n\n• Is general anesthesia (GA) better than procedural sedation (PS) for improving functional performance and decrease dependance in daily life 3 months after stroke?\n\nGA (a non-arousable state induced by anesthetic medications that require respiratory assistance) or PS (a state of reduced arousal induced by lesser dose of anesthetic medications that do not require respiratory assistance) are both used for MT. GA enables strict immobility that could facilitate the conduct of MT but lessen blood pressure and blood flow in the brain. PS provides less drop in blood pressure but MT could be more difficult due to possible movement and breathing may be decreased.\n\nResearchers will compare GA with PS to see which one is better for MT success and for the functional consequences of stroke.\n\nParticipants will be treated with GA or PS for the intervention of MT and will be followed by researchers during their hospital stay and asked by a telephone interview how is their functional status 3 months after stroke.",[99,277,278,279,29],"Anterior Cerebral Circulation","General Anesthesia","Procedural Sedation",[281,282,283,284,285,286,287,288],"Ischemic stroke","anterior circulation","mechanical thrombectomy","anesthetic strategy","general anesthesia","procedural sedation","functional outcome","large vessel occlusion stroke","2025-11-17",{"date":291,"type":39},"2025-11-19",{"date":293,"type":21},"2025-12-01",{"date":295,"type":21},"2029-03-01",{"name":297,"class":45},"University Hospital, Clermont-Ferrand",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":315,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":113},"100443207","phase-2-co2-modulation-in-endovascular-thrombectomy-for-acute-ischemic-stroke-100443207","NCT05051397","CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke","Evaluation of the Effect of Moderate and Controlled Hypercapnia on Ischemic Penumbra Vascular Collaterality During General Anesthesia for Anterior Circulation Acute Ischemic Stroke Mechanical Thrombectomy","COMET-AIS","Inclusion Criteria:\n\n• Large vessel occlusion anterior circulation stroke (terminal carotid artery and\u002For middle cerebral artery M1-M2 segment) eligible to mechanical thrombectomy under general anesthesia\n\nExclusion Criteria :\n\n* Active smoker\n* Chronic respiratory failure with ambulatory oxygen supplementation\n* Obesity with BMI\\>40Kg\u002F m2\n* Intubation before the procedure\n* Heart failure with intolerance to decubitus\n* Severe renal failure\n* Suspected elevated intracranial pressure\n* Pregnant or breastfeeding women",{"count":307,"type":21},50,[207],"Acute ischemic stroke due to large vessel occlusion is responsible of cerebral blood flow impairment with a progressive and extensive ischemic process. Cerebral collateral circulation may preserve an ischemic penumbra that could recover providing timely reperfusion of the occluded vessel. Mechanical thrombectomy is the standard of care for anterior circulation large vessel reperfusion. Strategy to promote cerebral blood flow in collateral circulation before reperfusion is scarce and rely mainly on blood pressure maintenance. Carbon dioxide is a potent cerebral vasodilator that could enhance collateral circulation blood flow and cerebral protection before reperfusion. General anesthesia with endotracheal mechanical ventilation could be used for thrombectomy and give the opportunity to modulate and control carbon dioxide tension in the blood. This study will test the effect of moderate hypercapnia on penumbral collateral circulation before reperfusion during mechanical thrombectomy for anterior circulation acute ischemic stroke under general anesthesia.",[311,29,312,313,314],"Ischemic Stroke, Acute","Anesthesia, General","Cerebrovascular Circulation","Carbon Dioxide",[283,288,316,317,285,318],"carbon dioxide tension","cerebral blood flow","cerebral collateral circulation","2025-09-30",{"date":321,"type":39},"2025-10-06",{"date":323,"type":39},"2022-07-20",{"date":325,"type":21},"2026-10-19",{"name":297,"class":45},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100510723","results-of-the-use-of-two-stentrievers-simultaneosly-compared-with-one-as-a-primary-treatment-in-acute-ischemic-stroke-100510723","NCT05930145","Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke","A Randomized Study Comparing the Effectiveness and Security of the Use of Two Stentrievers Simultaneously Versus One Stentriever as a Primary Treatment in Acute Ischemic Stroke Patients.","DIVERSO","Inclusion Criteria:\n\n* A new disabling focal neurological deficit compatible with acute cerebral ischemia.\n* Any age. Informed consent obtained from the patient or representative.\n* NIHSS score ≥ 6.\n* Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale.\n* Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography).\n* ASPECTs score on baseline CT greater than or equal to 6.\n* In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center.\n\nExclusion Criteria:\n\n* Those described in the usual protocols for mechanical thrombectomy of each hospital.\n* Pre-existing functional clinical status greater than 2 according to the mRS clinical scale\n* Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery.\n* Initiation of treatment with a different technique than the one described.\n* Inability to use a proximal balloon guide catheter.\n* Use of aspiration catheter.\n* Intracranial atherosclerotic plaque as the cause of occlusion.\n* Advanced or terminal disease with a life expectancy of less than 6 months.\n* Patient who is participating in another study that may affect this one.\n* ASPECTS score less than or equal to 6 on baseline CT.\n* Evidence of significant hemorrhage or mass effect with midline shift on baseline CT.\n* Patients with occlusions in multiple vascular territories.\n* Evidence of intracranial tumor (except for small meningiomas)",{"count":336,"type":21},200,[24],"Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c\u002F3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.",[103,29,340],"Arterial Occlusive Diseases",[103,342,29],"Double Stentriever","2025-07-24",{"date":345,"type":39},"2025-07-28",{"date":347,"type":39},"2025-03-14",{"date":349,"type":21},"2026-10-01",{"name":351,"class":45},"Fundación EPIC",4,{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":113},"100598281","prognostic-value-of-isolated-and-combined-score-aspects-in-acute-ischemic-stroke-100598281","NCT07069452","Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke","TARGET-ASPECT (Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke)","Inclusion Criteria :\n\n* Patients aged 18 years or older\n* Confirmed acute ischemic stroke on imaging\n* Treated with both thrombolysis and thrombectomy\n* Clinical follow-up data available at 90 days (mRS score)\n\nExclusion Criteria :\n\n* Primary hemorrhagic stroke\n* Early death or loss to follow-up without evaluation\n* Poor-quality imaging that cannot be analyzed",{"count":361,"type":21},152,"This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.",[364,29,365,175,366,367,368],"Stroke, Ischemic","Thrombolytic Therapy","Prognosis","Magnetic Resonance Imaging","Outcome Assessment (Health Care)","2025-07-15",{"date":371,"type":39},"2025-07-16",{"date":373,"type":39},"2025-04-15",{"date":108,"type":21},{"name":376,"class":45},"Centre Hospitalier de Gonesse",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":113},"100514223","the-effect-of-functional-electrical-stimulating-on-physical-activity-and-quality-of-life-in-patients-with-paralis-after-thrombectomy-a-randomized-controlled-study-100514223","NCT05975697","The EFFECT of FUNCTIONAL ELECTRICAL STIMULATING on PHYSICAL ACTIVITY and QUALITY of LIFE in PATIENTS with PARALIS AFTER THROMBECTOMY: a RANDOMIZED CONTROLLED STUDY","Inclusion Criteria:\n\n* Over 18 years old,\n* Thrombectomy procedure was performed,\n* Glasgow Coma Score (GCS) \\> 12 after thrombectomy\n* Able to communicate,\n* Having upper extremity paralysis,\n* No pacemaker, advanced spasticity and muscle atrophy, peripheral lesions, osteoporosis, skin irritation and obesity,\n* No skin and peripheral circulation problems,\n* Patients whose relatives gave consent to the research.\n\nExclusion Criteria:\n\n* Patients who did not comply with the sampling criteria and who developed complications that caused brain damage during the study (convulsions, mental disorder\u002Fdelirium, vomiting, tremor, myoclonus) and whose relatives did not approve of the study will not be included in the study.",{"count":384,"type":21},60,[24],"It is planned as a randomized controlled intervention study to determine the effect of functional electrical stimulation (FES) on physical activity and quality of life in patients with paralysis after thrombectomy.",[29],[29,389,390,391,392],"FES","PHYSICAL ACTIVITY","LIFE QUALITY","Nursing","2025-03-07",{"date":395,"type":39},"2025-03-11",{"date":397,"type":39},"2023-07-20",{"date":399,"type":21},"2025-04-01",{"name":401,"class":45},"Cukurova University",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":409,"targetDuration":95,"studyType":58,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":113},"100505688","acute-ischemic-stroke-endovascular-therapy-a-multicenter-registry-study-100505688","NCT05864638","Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study","Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study （OCIN-AIS-EVT REGISTRY）","Inclusion Criteria:\n\n1. Acute ischemic stroke caused by anterior or posterior circulation vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA)\n2. Undergo intravascular therapy (i.e. access to a cath lab and an arterial puncture)\n3. The patient or his\u002Fher legal representative agreed to participate in the study and has signed the informed consent.\n\nExclusion Criteria:\n\n1\\) No exclusion criteria",{"count":410,"type":21},10000,"A Multicenter Registry of Endovascular Treatment for Acute Ischemic Stroke.",[27,28,29,413],"Thrombosis","2025-01-23",{"date":416,"type":39},"2025-01-27",{"date":418,"type":39},"2023-05-10",{"date":420,"type":21},"2028-08-31",{"name":422,"class":45},"Changhai Hospital",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":249,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":46},"100573058","accelerating-referral-for-thrombectomy-in-acute-stroke-patients-using-an-artificial-intelligence-based-software-100573058","NCT06741332","Accelerating Referral for Thrombectomy in Acute Stroke Patients Using an Artificial Intelligence-based Software","CATalyze-AI","Inclusion Criteria:\n\n1. Suspected acute stroke patients\n2. \\>18 years with no upper age limit\n3. Included \\< 24 h since last seen well\n4. Non-contrast CT is available at the local stroke center\n5. Image has been processed by Methinks Stroke Suite\n6. Informed consent obtained from a patient or his or her legally designated representative (if locally required).\n\nExclusion Criteria:\n\n1. Patients in a coma (NIHSS item of consciousness \\>1)\n2. Patients with unstable clinical status who require emergent life support care\n3. Subject imaging does not meet Image Acquisition and DICOM Tag Requirements",{"count":431,"type":21},250,"The goal of this clinical trial is to learn if an AI-based imaging software, Methinks Stroke Suite, can reduce the time to transfer stroke patients who need thrombectomy from local stroke centers to specialized centers. The study focuses on acute stroke patients who are initially evaluated at local stroke centers that cannot perform endovascular therapy (EVT). The main questions it aims to answer are:\n\n* Does Methinks Stroke Suite reduce the time it takes to decide if a patient needs to be transferred for thrombectomy?\n* How accurate is the AI software in identifying patients who are candidates for EVT?\n\nResearchers will compare the AI-based workflow to a historical cohort to see if the Methinks Stroke Suite improves transfer decisions and treatment times.\n\nParticipants will:\n\n* Undergo a CT scan at the local stroke center, which will be analyzed by Methinks Stroke Suite.\n* Be transferred to a thrombectomy-capable center if the AI + clinical judgment identifies them as potential EVT candidates.\n* Be followed for 90 days after their stroke to assess recovery outcomes.",[103,434,311,29],"Stroke Acute",[103,99,436,437,438],"Acute stroke","mDIDO","Artificial Intelligence","2024-12-16",{"date":441,"type":39},"2024-12-18",{"date":443,"type":39},"2024-01-27",{"date":445,"type":21},"2026-03",{"name":447,"class":45},"Hospital Universitari Vall d'Hebron Research Institute",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":113},"100566376","thrombectomy-versus-best-medical-management-in-large-vessel-occlusion-stroke-patients-presenting-beyond-24-hours-and-with-presence-of-collateral-flow-on-ct-angiography-100566376","NCT06654375","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography: A Multicentre, Open-label, Registry-linked, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Confirmation of ICA or MCA-M1 occlusion, as detected by MRA or CTA, with carotid occlusions potentially occurring in either the cervical or intracranial regions, and the possibility of accompanying tandem MCA lesions.\n2. Demonstration of moderate to good collateral flow, as evidenced by CTA imaging.\n3. The patient must be aged 18 years or older.\n4. The baseline NIHSSS score is equal to or greater than 2, and this score remains equal to or greater than 2 immediately prior to randomization.\n5. Endovascular treatment can be initiated (via femoral puncture) within a window of 24 to 72 hours from the onset of the stroke. The onset of the stroke is defined as the time the patient was last known to be at their neurologic baseline (patients with wake-up strokes are eligible if they meet the aforementioned time constraints).\n6. There must be no significant pre-stroke disability, as indicated by a pre-baseline modified Rankin Scale score of 0-2.\n7. The patient must be willing and able to return for the protocol-required follow-up visits.\n8. The patient or their legally authorized representative must have signed the Informed Consent form.\n\nExclusion Criteria:\n\n1. The subject has a serious, advanced, or terminal illness (as determined by the investigator) or a life expectancy of less than six months.\n2. The subject has a pre-existing medical, neurological, or psychiatric disease that would interfere with neurological or functional evaluations, or is already participating in another drug or device study.\n3. The subject is pregnant.\n4. The subject has contraindications for both MRI and CT contrast that prevent an MRI or CT contrast perfusion study. The hospital's local standard criteria should be applied to determine if contraindications exist.\n5. The subject has a known allergy to iodine and has previously been refractory to pretreatment medications.\n6. The subject has been treated with tPA more than 4.5 hours after the last known well time.\n7. The subject has a known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or has recently undergone oral anticoagulant therapy with an INR greater than 3.\n8. The subject has symptoms consistent with stroke in multiple locations.\n9. The subject has seizures at stroke onset, which makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.\n10. The subject has a baseline blood glucose level of less than 50mg\u002FdL (2.78 mmol) or greater than 400mg\u002FdL (22.20 mmol).\n11. The subject has a baseline platelet count of less than 50,000\u002FuL.\n12. The subject has severe, sustained hypertension (Systolic Blood Pressure \\>185 mmHg or Diastolic Blood Pressure \\>110 mmHg) that is not treatable with medications.\n13. The subject is currently participating in another investigational drug or device study or registry.\n14. The subject is presumed to have a septic embolus, suspicion of bacterial endocarditis, or cerebral vasculitis.\n15. The subject has had clot retrieval attempted using a neurothrombectomy device within 24 hours of symptom onset.",{"count":456,"type":21},350,[24],"The goal of this clinical trial is to investigate if endovascular treatment (EVT) can effectively treat patients with large vessel occlusion (LVO) who present beyond the typical 24-hour window after symptom onset. The main questions it aims to answer are:\n\n* Can EVT improve functional independence at 90 days for patients treated after 24 hours?\n* What is the safety profile of EVT in this delayed treatment group compared to best medical management (BMM)? Researchers will compare EVT outcomes in patients presenting after 24 hours to those receiving BMM to see if EVT offers significant benefits.\n\nParticipants will:\n\n* Receive either EVT or BMM based on their eligibility.\n* Undergo CT angiography to assess collateral circulation and to confirm the presence of LVO.\n* Be followed for 90 days to evaluate functional outcomes and safety measures.",[434,29,460,28],"Medical Treatment",[462,32,27],"CTA","2024-10-22",{"date":465,"type":39},"2024-10-23",{"date":467,"type":39},"2024-06-25",{"date":216,"type":21},{"name":470,"class":45},"Tianjin Huanhu Hospital"]